Pacira BioSciences, Inc.
Summary
This filing is NOT a Rule 506(b) or 506(c) Form D for capital raising. It is a Form DEFA14A — a notice regarding a definitive proxy material filing by Pacira BioSciences, Inc. (ticker: PCRX), a publicly traded company. No new capital was raised via this filing; the $65.0M figure appears to be a data entry error and does not represent proceeds from a private placement.
See which stocks are affected
Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.
Already have an account? Log in
Full Analysis
Executive Summary
This filing is NOT a Rule 506(b) or 506(c) Form D for capital raising. It is a Form DEFA14A — a notice regarding a definitive proxy material filing by Pacira BioSciences, Inc. (ticker: PCRX), a publicly traded company. No new capital was raised via this filing; the $65.0M figure appears to be a data entry error and does not represent proceeds from a private placement.
Investor Edge
Ignore this filing for private placement intelligence. Sophisticated investors should check Pacira's definitive proxy statement filed under the same accession number for any shareholder proposals or board changes.
Sector capital positioning
No genuine private capital signal; the company is a public biopharmaceutical firm focused on non-opioid pain management, not a 'Technology Venture' as mislabeled. This filing does not reflect sector capital flows.
Convergence Signals
None. Filing is an SEC-required proxy disclosure unrelated to a capital raise, patents, contracts, or legislation.
Key Takeaways
- This is a proxy filing, not a private placement; $65.0M is not capital raised.
- Data incorrectly classifies a public biopharma as 'Technology Venture' and 'Unknown' state.
- No actionable intelligence for private capital investors from this filing.
Risk Indicators & Flags
MISCLASSIFIED FILING TYPE: DEFA14A is not a Form D. Incorrect industry label and capital amount suggest a data scraping or parsing error. No genuine regulatory or offering risk.
Verification & References
Verify the filer: SEC EDGAR search for '0001396814' shows Pacira BioSciences as a public company (CRX:PCRX). Accession 000162828026039589 is for a DEFA14A, not a Form D. The industry 'Technology Venture' is inconsistent with a biopharma company. The $65.0M 'Capital Raised' field is likely a data mapping error.
Connected Signals
Matched on shared policy language across AI analyses, with ticker & timing weight
Matthias Therapeutics, LLC
Uniform Bio Inc.
Dare Bioscience, Inc.
Anika Therapeutics, Inc.
DEF 14A - Outlook Therapeutics, Inc.
Outlook Therapeutics, Inc.
Strategy Inc
Related Presidential Actions
Executive orders & memoranda affecting the same sectors or companies
Advancing Regenerative Agriculture and Strengthening American Farm Resilience
This executive order directs the EPA, USDA, and HHS to prioritize registration of alternative pesticides, expedite cumulative exposure research, and maximize funding for a regenerative agriculture pilot program, while creating public-private partnerships to expand adoption of conservation farming practices. The order specifically instructs the EPA Administrator to speed up registration actions for substances that can replace older active ingredients, and requires HHS to issue a grand prize challenge for cumulative chemical exposure evaluation technologies.
Ushering in the Next Frontier of Quantum Innovation
This executive order updates the National Quantum Strategy and establishes a national effort (QC-ADDS) to develop a quantum computer for scientific discovery, with deployment at a Department of Energy facility. It directs multiple agencies to prioritize quantum sensing, networking, and supply chain initiatives, and mandates plans for commercial readiness and national security applications.
Securing the Nation Against Advanced Cryptographic Attacks
This executive order mandates a nationwide transition of federal information systems and critical infrastructure to post-quantum cryptography (PQC) by specific deadlines (2030 for key establishment, 2031 for digital signatures), directs NIST to lead technical guidance and a pilot project, requires agencies to appoint PQC migration leads, and orders the Federal Acquisition Regulatory Council to propose rules requiring contractors to comply with NIST PQC standards by 2030.
Free — no credit card
Get the next market-moving signal before the news does
HillSignal scores every Congressional bill, federal contract, and insider filing for market impact and emails you the high-conviction ones — free, no credit card.
Weekly digest — the congressional activity that actually moved markets that week, in plain English. Free, one email.
Free forever plan · No credit card · Unsubscribe in one click
Want the live terminal too? Create a free account →